Once we confirmed that the inositol polyphosphates-dependent strategy was successful in blocking Akt activation in vitro and in vivo, we focused our attention on the possibility of improving the anti-cancer activity of InsP5 by designing novel synthetic compounds based on the structure of this inositol polyphosphate. This evidence concerns the gene AKT1 and cancer.